MedPath
HSA Approval

Propofol-Lipuro 2% (20mg/ml)

SIN13622P

Propofol-Lipuro 2% (20mg/ml)

Propofol-Lipuro 2% (20mg/ml)

March 23, 2009

B. BRAUN SINGAPORE PTE LTD

B. BRAUN SINGAPORE PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantB. BRAUN SINGAPORE PTE LTD
Licence HolderB. BRAUN SINGAPORE PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

EMULSION

**Dosage** _General instructions_ Propofol-Lipuro 2 % (20 mg/ml) must only be given in hospitals or adequately equipped day therapy units by physicians trained in anaesthesia or in the care of patients in intensive care. Circulatory and respiratory functions should be constantly monitored (e.g. ECG, pulse-oxymeter) and facilities for maintenance of patent airways, artificial ventilation, and other resuscitation facilities should always be immediately available. For sedation during surgical or diagnostic procedures Propofol-Lipuro 2 % (20 mg/ml) should not be given by the same person that carries out the surgical or diagnostic procedure. Supplementary analgesic medicinal products are generally required in addition to Propofol-Lipuro 2 % (20 mg/ml). Propofol-Lipuro 2 % (20 mg/ml) is given intravenously. The dosage is adjusted individually according to the patient’s response. _General anaesthesia in adults_ Induction of anaesthesia For induction of anaesthesia Propofol-Lipuro 2 % (20 mg/ml) should be titrated (20 – 40 mg of propofol every 10 seconds) against the patient’s response until the clinical signs show the onset of anaesthesia. Most adult patients younger than 55 years are likely to require 1.5 to 2.5 mg of propofol/kg BW. In older patients and in patients of ASA grades III and IV, especially those with impaired cardiac function, the dosage requirements will be less and the total dose of Propofol-Lipuro 2 % (20 mg/ml) may be reduced to a minimum of 1 mg of propofol/kg BW. In these patients lower rates of administration should be applied (approximately 1 ml, corresponding to 20 mg, every 10 seconds). Maintenance of anaesthesia Anaesthesia is maintained by administering Propofol-Lipuro 2 % (20 mg/ml) by continuous infusion. The dosage requirements usually are in the range of 4 – 12 mg of propofol/kg BW/h. In the elderly, in patients of poor general condition, in patients of ASA grades III and IV and in hypovolaemic patients the dosage may be reduced further depending on the severity of the patient’s condition and on the performed anaesthetic technique. _General anaesthesia in children over 3 years of age_ Induction of anaesthesia For induction of anaesthesia Propofol-Lipuro 2 % (20 mg/ml) should be titrated slowly against the patient’s response until the clinical signs show the onset of anaesthesia. The dosage should be adjusted according to age and/ or BW. Most patients over 8 years are likely to require approximately 2.5 mg of propofol/kg BW for induction of anaesthesia. Below this age the dose requirement may be higher (2.5 – 4 mg of propofol/kg BW). Due to the lack of clinical experience, lower dosages are recommended for young patients at increased risk (ASA grades III and IV). Propofol-Lipuro 2 % (20 mg/ml) is contraindicated for induction of anaesthesia in children below 3 years of age. Maintenance of general anaesthesia: For maintenance of general anaesthesia, a satisfactory level of anaesthesia is usually achieved by continuous infusion with a dosage regimen in the range of 9 – 15 mg of propofol/kg BW/h. Dosage should be adjusted individually and particular attention paid to the need for adequate analgesia (see also “General instructions” above). Propofol-Lipuro 2 % (20 mg/ml) is contraindicated for maintenance of anaesthesia in children below 3 years of age. _Sedation of ventilated patients in the intensive care unit_ When used to provide sedation for ventilated patients under intensive care conditions, it is recommended that Propofol-Lipuro 2 % (20 mg/ml) be given by continuous infusion. The infusion rate should be adjusted according to the required depth of sedation. Usually satisfactory sedation is achieved with administration rates in the range of 0.3 – 4.0 mg of propofol/kg BW/h. (See also **“Special warnings and precautions for use”** – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Propofol is not indicated for sedation in the intensive care unit of patients of 16 years of age or younger (see **“Contraindications”**). _Sedation for diagnostic and surgical procedures in adult patients_ To provide sedation during surgical and diagnostic procedures, doses and administration rates should be adjusted according to the clinical response. Most patients will require 0.5 – 1 mg of propofol/kg BW over 1 to 5 minutes for onset of sedation. Maintenance of sedation may be accomplished by titrating Propofol-Lipuro 2 % (20 mg/ml) infusion to the desired level of sedation. Most patients will require 1.5 – 4.5 mg of propofol/kg BW/h. The infusion may be supplemented by bolus administration of 10 – 20 mg of propofol (0.5 – 1 ml Propofol-Lipuro 2 % (20 mg/ml)) if a rapid increase of the depth of sedation is required. In patients older than 55 years and in patients of ASA grade III and IV lower doses of Propofol-Lipuro 2 % (20 mg/ml) may be required and the rate of administration may need to be reduced. Propofol-Lipuro 2 % (20 mg/ml) must not be used for sedation for diagnostic and surgical procedures in patients of 16 years or younger. _Duration of use_ Propofol-Lipuro 2 % (20 mg/ml) can be administered for a maximum period of 7 days.

INTRAVENOUS

Medical Information

**Indications** Propofol-Lipuro 2 % (20 mg/ml) is a short-acting intravenous general anaesthetic for - induction and maintenance of general anaesthesia in adults and for use in children above 3 years of age - sedation of ventilated adult patients (above 16 years of age) in the intensive care unit - sedation of adult patients (above 16 years of age) for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia.

**Contraindications** Propofol-Lipuro 2 % (20 mg/ml) must not be used: - in patients with known hypersensitivity to propofol or to any of the constituents of the emulsion, - in patients who are allergic to soya or peanut, - in children younger than 3 years for induction and maintenance of anaesthesia, - in patients of 16 years of age or younger for sedation in intensive care. - in high doses during pregnancy, and obstetric anaesthesia with the exception of termination of pregnancy

N01AX10

propofol

Manufacturer Information

B. Braun Singapore Pte Ltd.

B. Braun Melsungen AG

Active Ingredients

Propofol

20.0mg/ml

Propofol

Documents

Package Inserts

Proposed 12 V1 12608081_Propofol_IL_GIF_210x594_SG_599.pdf

Approved: September 21, 2021

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Propofol-Lipuro 2% (20mg/ml) - HSA Approval | MedPath